Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01328769 · ClinicalTrials.gov registry record · Phase 4
Febuxostat, Blood Pressure and the Intrarenal Renin-Angiotensin System (RAS)
A Phase 4 study of Hypertension, sponsored by Paul N. Hopkins.
- Completed
- Registry status
- Phase 4
- Development phase
- 49
- Enrollment target
- 1
- Study location
NCT01328769: Completed Phase 4 study of Hypertension, sponsored by Paul N. Hopkins.
NCT01328769 is a Phase 4 study of Hypertension that has completed, run by Paul N. Hopkins. The registered enrollment target is 49 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01328769, a Phase 4 study of Hypertension, has completed, sponsored by Paul N. Hopkins.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 49 participants
- Enrollment target
- 1
- Study location
Study Summary
In this study the investigators will recruit hypertensive subjects with higher than average uric acid levels to test the effect of lowering uric acid with febuxostat on several measures as listed below. This will be a randomized, double-blind, placebo-controlled, parallel group study.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Febuxostat
Study Locations (1)
Utah
- Cardiovascular Genetics, University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2011-03 |
| Est. Completion | 2014-01 |
| Phase | Phase 4 |
What the finished NCT01328769 record still lists
NCT01328769 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01328769 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT01328769 about?
NCT01328769 is a clinical study titled "Febuxostat, Blood Pressure and the Intrarenal Renin-Angiotensin System (RAS)". In this study the investigators will recruit hypertensive subjects with higher than average uric acid levels to test the effect of lowering uric acid with febuxostat on several measures as listed below. This will be a randomized, double-blind, placebo-controlled, parallel group study.
What is the current status of trial NCT01328769?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 49 participants. The study started on 2011-03. Estimated completion is 2014-01.
What conditions does trial NCT01328769 study?
This clinical trial studies the following conditions: Hypertension.
What interventions are being tested in trial NCT01328769?
The interventions under investigation include: Placebo (DRUG), Febuxostat (DRUG).
Who is sponsoring clinical trial NCT01328769?
This trial is sponsored by Paul N. Hopkins, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01328769 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01328769's enrollment target sits among peer trials
49 376th of 470 higher than 94 of 470 other Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treatment With Aspirin After Preeclampsia: TAP Trial
RECRUITING · Phase 4
-
Impact GLP-1 Agonists Following Bariatric
RECRUITING · Phase 4
-
Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study
RECRUITING · Phase 4
-
Bridging the Evidence-to-practice Gap
RECRUITING · Phase 4
-
Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension
RECRUITING · Phase 4
-
Secondhand Tobacco Smoke and Cardiovascular Disease
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia